Blog

Hagen Kennecke: First prospective trial to confirm benefit of adjuvant COX-2 in PIK3CA activated colon cancer

Photo of Hagen Kennecke from ohsu.edu

Jul 10, 2024, 15:30

Hagen Kennecke: First prospective trial to confirm benefit of adjuvant COX-2 in PIK3CA activated colon cancer

Hagen Kennecke, Section chief and Chief Health Officer of the OHSU Knight-Legacy Health Cancer Collaborative, shared a post on X:

”First prospective trial to confirm benefit of adjuvant COX-2 in PIK3CA activated colon cancer, OS HR=0.4.

Patients are asking: do we recommend COX-2 for the 20% with mutation PIK3CA?

Need to do NGS for all stage III CRC.”

Source: Hagen Kennecke/X

Anthony F Shields Ardaman Shergill Benjamin Tan cancer Chao Ma Charles S Fuchs Colon cancer Eileen M. O'Reilly Felix Couture Hagen Kennecke James Knight Jeffrey A Meyerhardt Jonathan A Nowak Juha Väyrynen Kenji Fujiyoshi Koichiro Haruki Melissa Zhao OncoDaily Oncology Pankaj Kumar Philip Kuebler Philip Philip Qian Shi Shrikant Mane Shuji Ogino Smitha Krishnamurthi Tyler Twombly

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage